|
|
|
22.07.25 - 15:33
|
MTTI Announces Dr. Danielle Meyrick to Lead Medical Team (Business Wire)
|
|
|
WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) today announced the appointment of Danielle Meyrick, PhD, MD, as Chief Medical Officer. Dr. Meyrick brings more than 20 years of medical research, targeted radiotherapeutic (TRT) development and leadership to MTTI. She has held Chief Medical Officer roles across radiopharmaceutical organizations including Telix Pharmaceuticals and ITM Radiopharm. Dr. Meyrick will lead MTTI's medical team to advance clinical development of lead assets, EVA101 and EVA 102 and further progress the company's radiopharmaceutical pipeline.
“My career goal in the TRT area has always been to improve care and outcomes for cancer patients. I believe MTTI is an exciting company with technology that is able to deliver on this goal. Our unique EvaThera platform has demonstrated the ability to enhance delivery of radiation to tumors, minimize off-target activity and reduce dosing requirements —collectively offering a potentially safer, more effectiv...
|
|
|
|
|
22.07.25 - 10:09
|
Telix Reports $204M Revenue, Up 63% YOY (GlobeNewswire EN)
|
|
|
MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise....
|
|
|
|
|
10.07.25 - 00:48
|
Gozellix Receives Permanent HCPCS Code (GlobeNewswire EN)
|
|
|
MELBOURNE, Australia and INDIANAPOLIS, July 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that its next-generation PSMA1 PET2 imaging agent, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code by the U.S. Centers for Medicare & Medicaid Services (CMS)....
|
|
|
|
|
09.07.25 - 04:48
|
Telix shares jump 7% on big US news (Fool)
|
|
|
Let's see what is getting investors excited on Wednesday.
The post Telix shares jump 7% on big US news appeared first on The Motley Fool Australia....
|
|
|
|
|
23.06.25 - 13:18
|
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT (GlobeNewswire EN)
|
|
|
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting....
|
|
|
|
|
|
|
|
|
|
|
11.06.25 - 13:03
|
Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S. (GlobeNewswire EN)
|
|
|
MELBOURNE, Australia and INDIANAPOLIS, June 11, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that its next-generation PSMA-PET imaging1 agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is now commercially available nationally in the United States (U.S.)....
|
|
|
|
|
05.06.25 - 08:18
|
Telix′s Illuccix® PSMA-PET Imaging Agent Approved in Germany (PR Newswire)
|
|
|
MELBOURNE, Australia, June 5, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted......
|
|
|
03.06.25 - 13:00
|
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs (GlobeNewswire EN)
|
|
|
MELBOURNE, Australia and INDIANAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) provides further details on the agenda for the Company's Investor Day to be held on Wednesday, June 11, 2025, at The Yale Club in New York City, from 8.30am ET (10.30pm AEST) to 12.00pm ET....
|
|
|
|
|
30.04.25 - 09:15
|
Telix Pharma: Bitterer FDA-Rückschlag, aber... (Der Aktionaer)
|
|
|
Herber Rückschlag für Telix Pharmaceuticals: Die US-Zulassungsbehörde FDA hat die Vertriebsgenehmigung des Diagnostik-Produkts Pixclara zur Bildgebung von Hirntumoren verweigert. Dafür kann der Radiopharma-Spezialist aus Down Under mit zwei weiteren Zulassung für den Top-Seller Illuccix in Europa punkten....
|
|
|
29.04.25 - 00:36
|
Telix′s Illuccix PSMA-PET Imaging Agent Approved in France (PR Newswire)
|
|
|
New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent MELBOURNE, Australia, April 29, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent,......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
